Search research articles
Contact Us
Filters
Showing results (91-100 of 114) with videos related to
Page
of 12
Sort By:
The Journal of Urology
|
August 19, 2022
Reply by Authors
Sophia M Abusamra, Marissa A Solorzano, Mallory Luke, et al.
European Urology Open Science
|
April 17, 2026
Germline Variants in Bladder and Upper Tract Urothelial Cancers: Prevalence and Clinical Context in a Large Testing Registry
Steven M Monda, Eugene Oh, Patrick J Lewicki, et al.
The Journal of Urology
|
August 5, 2022
Satisfaction With Clinician-Led Germline Genetic Counseling in Patients With Prostate Cancer
Sophia M Abusamra, Marissa A Solorzano, Mallory Luke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 30, 2021
A Comprehensive Assessment of <sup>68</sup>Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
Monica Abghari-Gerst, Wesley R Armstrong, Kathleen Nguyen, et al.
International Journal of Molecular Sciences
|
January 11, 2022
Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Zachery R Reichert, Tadas Kasputis, Srinivas Nallandhighal, et al.
Cancer Cell
|
June 13, 2018
BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation
Dan Zhu, Satoru Osuka, Zhaobin Zhang, et al.
JCO Precision Oncology
|
September 16, 2025
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)
Irene Tsung, David C Smith, Elisabeth I Heath, et al.
ESMO Open
|
September 10, 2024
Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing
D Triner, R P Graf, R W Madison, et al.
JCO Precision Oncology
|
May 29, 2020
<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
Cancer Research Communications
|
June 1, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study
Rahul R Aggarwal, Antoine Italiano, Susan M Domchek, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 114) with videos related to
Sort By:
Page
of 12
The Journal of Urology
|
August 19, 2022
Reply by Authors
Sophia M Abusamra, Marissa A Solorzano, Mallory Luke, et al.
European Urology Open Science
|
April 17, 2026
Germline Variants in Bladder and Upper Tract Urothelial Cancers: Prevalence and Clinical Context in a Large Testing Registry
Steven M Monda, Eugene Oh, Patrick J Lewicki, et al.
The Journal of Urology
|
August 5, 2022
Satisfaction With Clinician-Led Germline Genetic Counseling in Patients With Prostate Cancer
Sophia M Abusamra, Marissa A Solorzano, Mallory Luke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 30, 2021
A Comprehensive Assessment of <sup>68</sup>Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
Monica Abghari-Gerst, Wesley R Armstrong, Kathleen Nguyen, et al.
International Journal of Molecular Sciences
|
January 11, 2022
Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Zachery R Reichert, Tadas Kasputis, Srinivas Nallandhighal, et al.
Cancer Cell
|
June 13, 2018
BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation
Dan Zhu, Satoru Osuka, Zhaobin Zhang, et al.
JCO Precision Oncology
|
September 16, 2025
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)
Irene Tsung, David C Smith, Elisabeth I Heath, et al.
ESMO Open
|
September 10, 2024
Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing
D Triner, R P Graf, R W Madison, et al.
JCO Precision Oncology
|
May 29, 2020
<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
Cancer Research Communications
|
June 1, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study
Rahul R Aggarwal, Antoine Italiano, Susan M Domchek, et al.
Page
of 12